摘要
目的探讨洛匹那韦/利托那韦(LPV/r)治疗新型冠状病毒肺炎(COVID-19)患者药品不良反应(ADR)的临床特征、发生机制及一般规律,为临床合理用药提供参考。方法回顾性分析医院2020年1月1日至3月15日14例接受LPV/r治疗的COVID-19患者的临床资料,采用Excel软件分析患者的一般资料、用药情况、ADR及其转归。结果 14例患者中,12例患者发生ADR,男女比例相当;发生人群集中在41~50岁;平均用药疗程为(13.8±4.45) d。ADR中高三酰甘油血症构成比最高,其次为腹泻、胆红素血症、恶心呕吐、肝药酶升高等,无新发或严重ADR。ADR处理包括停药、药物干预、停药并药物干预,83.33%的患者在出院前治愈或好转,58.33%的患者在10 d内治愈或好转。12例患者中,11例有联合用药情况,联用最多的药物为抗感染药物。结论 LPV/r易发生ADR,但转归较好,很少出现停药情况。其所致ADR存在个体差异,多数为营养代谢异常、胃肠功能紊乱和肝胆损伤。密切监护、及时处理、用药疗程尽量不超过10 d是安全用药的有效手段。
Objective To investigate the clinical characteristics,mechanism and general rules of adverse drug reactions(ADR)induced by lopinavir/ritonavir in the treatment of patients with coronavirus disease(COVID-19),and to provide a reference for clinical rational drug use.Methods The clinical data of 14 patients with COVID-19 who treated with lopinavir/ritonavir in our hospital from January 1,2020 to March 15,2020 were collected,and the general condition,medication,occurrence and outcome of ADR were were analyzed by Excel.Results Among the 14 patients,12 patients had ADR,the ratio of male to female was equal.The occurrence of ADR was concentrated in 41-50 years old,the average medication course was(13.8±4.45)d,hypertriglyceridemia was the highest ADR,followed by diarrhea,bilirubinemia,nausea and vomiting,elevated liver enzymes,without new or severe ADR.The treatment of ADR included drug withdrawal,drug intervention,drug withdrawal and drug intervention.Before discharge,83.33%of patients were cured or improved,and58.33%of patients were cured or improved within 10 d.Among the 12 patients,11 patients had drug combination,and the most commonly used drugs were anti-infective drugs.Conclusion Lopinavir/ritonavir is prone to ADR,but the outcome rate is good with rarely drug withdrawal.There are individual differences in the ADR induced by lopinavir/ritonavir,but most of them are abnormal nutritional metabolism,gastrointestinal dysfunction,and liver and gallbladder damage.Close monitoring,timely treatment,and medication course of less than 10 d are effective means for safe medication.
作者
曾亚
徐珽
ZENG Ya;XU Ting(Department of Pharmacy,West China Hospital,Sichuan University,chengdu,sichuan,china 610041)
出处
《中国药业》
CAS
2021年第5期95-96,I0001-I0003,共5页
China Pharmaceuticals
基金
四川省科技计划项目[2020JDR0144]。
